Thinking of joining a study?

Register your interest

NCT05692505 | Not yet recruiting | HIV Infections


Multicenter Performance Study of QuadQuik In Vitro Diagnostic Device
Sponsor:

Genlantis Diagnostics

Brief Summary:

To Demonstrate Clinical Performance of the TriQuik In Vitro Diagnostic Device

Condition or disease

HIV Infections

Hepatitis C

Hepatitis B

Syphilis Infection

Intervention/treatment

QuadQuik

Detailed Description:

Measurement Methodology Whole blood samples are collected by fingerstick. Samples tested immediately. Using the supplied sample dropper, transfer specimen blood drop into the two sample wells. Wait 20-30 seconds. Add two drops of the supplied assay buffer (~90µL) to the same sample wells Read result in 20 mins. Primary end points will determine how accurate these tests are (p<=0.02) by analyzing for: Diagnostic Sensitivity; TP / (TP + FN) The ability of the test to correctly identify those patients with the disease Diagnostic Specificity; TN / (TN + FP) The ability of the test to correctly identify those patients who are truly free of the specific disease Positive Predictive Value: TP / (TP+ FP) The probability that subjects with a positive test truly have the disease. Negative Predictive Value: TN / (FN + TN) The probability that subjects with a negative test truly don't have the disease. An estimated 200 patients are to be enrolled as follows: 150 with a documented medical history of HIV, HBV, HCV or Syphilis. A combination of 2 or 3 conditions is acceptable. HbsAg patients need to have a HbsAg on file < 2 years. HIV and HCV or Syphilis patients only need one antibody test in their medical chart. 50 with no documented medical history of HIV, HBV, HCV or Syphilis and are considered normal. Male or female subjects, ages ≥18 years.}}

Study Type : Observational
Estimated Enrollment : 200 participants
Official Title : Multicenter Performance Study of QuadQuik In Vitro Diagnostic Device
Actual Study Start Date : April 1, 2023
Estimated Primary Completion Date : April 1, 2023
Estimated Study Completion Date : June 1, 2023

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Accepts Healthy Volunteers
Criteria
Inclusion Criteria
  • a documented medical history of HIV, HBV, HCV or syphilis. A combination of 2 or 3 conditions is acceptable.
  • HbsAg patients need to have a HbsAg on file < 2 years. HIV and HCV patients only need one antibody test in their medical chart. no documented medical history of HIV, HBV, HCV or syphilis and are considered normal.
  • Male or female subjects, ages ≥18 years. Signed informed consent provided by an authorized subject representative (based on local Institutional Review Board (IRB)/ethics panel requirements).-
Exclusion Criteria
  • Any other condition or prior therapy, which, in the opinion of the investigator, would make the subject unsuitable for this study.
  • Participation in any phase of another clinical research study involving the evaluation of another investigational drug or device within 30 days before randomization.-

Multicenter Performance Study of QuadQuik In Vitro Diagnostic Device

Location Details


Please Choose a site



Multicenter Performance Study of QuadQuik In Vitro Diagnostic Device

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Not yet recruiting

United States, California

Genlantis Diagnostics

San Diego, California, United States, 92121

Loading...